Welcome to our dedicated page for Zura Bio news (Ticker: ZURA), a resource for investors and traders seeking the latest updates and insights on Zura Bio stock.
Zura Bio Limited reports news on its clinical-stage immunology pipeline for autoimmune and inflammatory diseases. The company develops dual-pathway antibody candidates, led by tibulizumab (ZB-106), which targets IL-17A and BAFF and is being evaluated in Phase 2 studies for hidradenitis suppurativa and systemic sclerosis. Its additional clinical-stage candidates include crebankitug (ZB-168), targeting IL-7R, and torudokimab (ZB-880), targeting IL-33.
Recurring updates cover clinical study designs and presentations, financial results, corporate presentations, leadership and board changes, equity incentive grants, and capital-raising activity involving Class A ordinary shares and pre-funded warrants.
Zura Bio (Nasdaq: ZURA) granted an inducement option award to its new Chief Business Officer, Muzammil Mustufa, under Nasdaq Listing Rule 5635(c)(4). The option covers up to 600,000 Class A Ordinary Shares at an exercise price of $4.80 per share, vesting over four years.
Zura Bio (Nasdaq: ZURA), a clinical-stage biotech focused on autoimmune and inflammatory diseases, appointed Muzammil Mustufa as Chief Business Officer.
He will lead corporate strategy, business development, commercial planning, and investor relations as Zura advances its bispecific antibody tibulizumab toward key clinical and corporate milestones.
Zura Bio (Nasdaq: ZURA) reported Q1 2026 results and corporate updates. Cash and cash equivalents were $225.6M as of March 31, 2026, expected to fund operations through at least end of 2028. The company completed a February 2026 public offering raising ~$144M gross.
Tibulizumab Phase 2 programs continue: TibuSHIELD (HS) ~225 patients enrolled, topline data expected Q4 2026; TibuSURE (SSc) ~80 patients enrolled, topline data expected H1 2027. R&D and G&A expenses and net loss increased versus Q1 2025.
Zura Bio (Nasdaq: ZURA) announced inducement equity awards granted April 30, 2026: options to purchase 615,160 Class A shares were issued to eight newly hired employees outside the company’s 2023 Equity Incentive Plan under Nasdaq Listing Rule 5635(c)(4).
The options carry an exercise price of $5.08 (closing price on April 30, 2026) and vest over four years with a one‑year cliff and subsequent equal quarterly vesting, subject to continuous service and the Plan and award agreement terms.
Zura Bio (Nasdaq: ZURA) reported full year 2025 results and corporate updates on March 19, 2026. Key points: $109.4M cash as of December 31, 2025; completed a February 2026 public offering for ~$144M gross proceeds; pro‑forma cash expected to fund operations through at least end of 2028.
Clinical progress includes two ongoing Phase 2 tibulizumab studies: TibuSHIELD (HS) expanded to 225 participants with topline data expected Q4 2026, and TibuSURE (SSc) topline data expected H1 2027.
Zura Bio (Nasdaq: ZURA) announced that the Phase 2 TibuSURE trial design has been accepted for a poster presentation at the 9th Systemic Sclerosis World Congress, March 5–7, 2026 in Athens.
The poster (P.267) outlines the global, randomized, double-blind, placebo-controlled study of tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF, enrolling ~80 adults with diffuse cutaneous systemic sclerosis, 24-week randomized dosing and a 28-week open-label extension. Primary endpoint: change in modified Rodnan Skin Score at Week 24. Topline results anticipated H1 2027.
Zura Bio (Nasdaq: ZURA) said members of management will attend two investor events in Miami: a Leerink Global Healthcare Conference fireside chat on March 10, 2026 at 2:20 p.m. ET and investor meetings at Jefferies Biotech on the Beach on March 11, 2026.
A live webcast of the Leerink fireside chat will be available in the company’s Investors section, with a replay accessible for at least 30 days following the event.
Zura Bio (Nasdaq: ZURA) closed an underwritten public offering on February 26, 2026, raising approximately $144 million gross. The offering sold 21,200,000 Class A shares at $6.25 and pre-funded warrants for 1,800,000 shares at $6.249. Underwriters exercised an option for an additional 3,000,000 shares, and all securities were sold by Zura. Joint bookrunners were Leerink Partners, Piper Sandler and Cantor; Wedbush PacGrow acted as lead manager. The offering was made under a Form S-3 registration declared effective September 17, 2024.
Zura Bio (Nasdaq: ZURA) priced an underwritten public offering of 18,200,000 Class A ordinary shares at $6.25 per share and 1,800,000 pre-funded warrants at $6.249 each. Zura granted a 30-day option for up to 3,000,000 additional shares. Gross proceeds are expected to be $125 million, and the offering is expected to close on February 26, 2026, subject to customary closing conditions.
Joint bookrunners are Leerink Partners, Piper Sandler and Cantor; Wedbush PacGrow is lead manager. The securities are offered under the company’s Form S-3 shelf registration (No. 333-281905).
Zura Bio (Nasdaq: ZURA) has commenced an underwritten public offering of Class A ordinary shares and, for certain investors, pre-funded warrants to buy Class A shares. The underwriters have a 30-day option to purchase up to 15% additional shares and shares underlying warrants. The offering is subject to market conditions and may not be completed as proposed. The securities will be offered pursuant to an existing Form S-3 shelf registration (No. 333-281905), declared effective September 17, 2024; a prospectus supplement will be filed with the SEC.